NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SABS
SAB Biotherapeutics, Inc.
There isn't enough reported data to score SABS yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SABS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SABS's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SABS PE Valuation
SABS has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SABS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect SABS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus SABS down 150%.
SABS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.09 | +$3.10 |
| Q2 2025 | -$4.00 | +$2.07 |
| Q1 2025 | -$3.70 | +$2.98 |
| Q4 2024 | -$3.68 | +$3.96 |
| Q3 2024 | -$6.19 | -$0.46 |
| Q2 2024 | -$6.07 | +$0.26 |
| Q1 2024 | -$6.68 | -$0.65 |
| Q4 2023 | -$7.64 | -$3.31 |
SABS is still losing money, but far less than before: $3.09 per share over the past year, against $9.10 at its worst in early 2022.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus down 62% for SABS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
SABS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $114.7K | -62% |
| Q2 2024 | $263.1K | +208% |
| Q1 2024 | $944.6K | +63% |
| Q4 2023 | $305K | -86% |
| Q3 2023 | $1.3M | -65% |
| Q2 2023 | $85.5K | -99% |
| Q1 2023 | $581.1K | -95% |
| Q4 2022 | $2.2M | -80% |
SABS's revenue has slid since its 2022 peak: $114,698 last quarter, down 62% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -8726% | -2538 points |
| Q2 2024 | -3877% | +3696 points |
| Q1 2024 | -1206% | +68 points |
| Q4 2023 | -6188% | -5824 points |
| Q3 2023 | -420% | -203 points |
| Q2 2023 | -7573% | -7470 points |
| Q1 2023 | -1274% | -1217 points |
| Q4 2022 | -364% | -297 points |
SABS's operating margin was −8726% last quarter, down 8306 points from the same quarter a year ago, near the bottom of its range since 2021.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with SABS at down 97%.
SABS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$9.6M | +$3.9M |
| Q3 2024 | -$6.4M | -$1.1M |
| Q2 2024 | -$7.8M | -$2.8M |
| Q1 2024 | -$10.9M | -$9.3M |
| Q4 2023 | -$13.5M | -$11.8M |
| Q3 2023 | -$5.3M | +$3M |
| Q2 2023 | -$4.9M | +$900.1K |
| Q1 2023 | -$1.6M | +$10M |
SABS has burned cash in almost every quarter: −$51M over the past year, against −$39M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SABS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SABS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +13.5M shares |
| 1 year | +903% | +83.9M shares |
| 3 years | +1750% | +88.2M shares |
| 5 years | +37195% | +93M shares |
SABS has 93M diluted shares, up 903% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SABS Net Leverage
SABS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SABS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 46.0 | Neutral |
SABS's weekly RSI is 45 (neutral) and its Stochastic is 46 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SABS PE vs Healthcare Sector
| Metric | SABS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SABS has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SABS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.01 | 2.3% above |
| 20 week MA | $3.41 | 9.7% below |
| 50 week MA | $3.66 | 16% below |
| 100 week MA | $3.02 | 2% above |
| 200 week MA | $4.35 | 29% below |
SABS has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SABS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $102.1 | $87.5 | -14% |
| 2022 | $87.5 | $6.90 | -92% |
| 2023 | $6.90 | $6.88 | -0.3% |
| 2024 | $6.88 | $4.18 | -39% |
| 2025 | $4.18 | $3.78 | -9.6% |
| 2026 YTD | $3.78 | $3.08 | -19% |
SABS has the edge over NVO on returns for 2026, with the stronger performance.